MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2023.1148798

Медицинская библиотека · Frontiers in immunology · 2023

Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma.

Willems Mégane, Scherpereel Arnaud, Wasielewski Eric, Raskin Jo, Brossel Hélène, Fontaine Alexis, Grégoire Mélanie, Halkin Louise, Jamakhani Majeed, Heinen Vincent, Louis Renaud, Duysinx Bernard, Hamaidia Malik, Willems Luc

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Only a fraction of patients with malignant pleural mesothelioma (MPM) will respond to chemo- or immunotherapy. For the majority, the condition will irremediably relapse after 13 to 18 months. In this study, we hypothesized that patients' outcome could be correlated to their immune cell profile. Focus was given to peripheral blood eosinophils that, paradoxically, can both promote or inhibit tumor growth depending on the cancer type.

METHODS

The characteristics of 242 patients with histologically proven MPM were retrospectively collected in three centers. Characteristics included overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR). The mean absolute eosinophil counts (AEC) were determined by averaging AEC data sets of the last month preceding the administration of chemo- or immunotherapy.

RESULTS

An optimal cutoff of 220 eosinophils/µL of blood segregated the cohort into two groups with significantly different median OS after chemotherapy (14 and 29 months above and below the threshold, p = 0.0001). The corresponding two-year OS rates were 28% and 55% in the AEC ≥ 220/µL and AEC < 220/µL groups, respectively. Based on shorter median PFS (8 vs 17 months, p < 0.0001) and reduced DCR (55.9% vs 35.2% at 6 months), the response to standard chemotherapy was significantly affected in the AEC ≥ 220/µL subset. Similar conclusions were also drawn from data sets of patients receiving immune checkpoint-based immunotherapy.

CONCLUSION

In conclusion, baseline AEC ≥ 220/µL preceding therapy is associated with worse outcome and quicker relapse in MPM.

Для цитирования: Willems Mégane, Scherpereel Arnaud, Wasielewski Eric, Raskin Jo, Brossel Hélène, Fontaine Alexis, Grégoire Mélanie, Halkin Louise, Jamakhani Majeed, Heinen Vincent, Louis Renaud, Duysinx Bernard, Hamaidia Malik, Willems Luc. Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma.. Frontiers in immunology. 2023. DOI: 10.3389/fimmu.2023.1148798.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.